Flash FinanceUS
Market open S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Integra Lifesciences (IART)

Integra LifeSciences amends credit agreement, raises leverage covenant limit

Mixed Impact 3 of 5 financing Written later

On June 6, 2025, Integra LifeSciences amended its credit agreement to raise the maximum consolidated total leverage ratio it must maintain, from 5.00 to 1.00 through June 30, 2026, then stepping down to 4.00 to 1.00 from March 31, 2027. The amendment also temporarily restricts certain investments, incremental borrowing, liens, restricted payments and intellectual property transfers, and the company states it does not increase total indebtedness.

Key points

  • Amendment dated June 6, 2025, to the Seventh Amended and Restated Credit Agreement dated March 24, 2023.
  • Maximum leverage ratio is 5.00 to 1.00 for quarters ending March 31, 2025 through June 30, 2026, then 4.75 (September 30, 2026), 4.50 (December 31, 2026) and 4.00 (March 31, 2027 onward).
  • Through the Covenant Relief Period, which runs until delivery of fiscal 2026 financial statements, limits apply to investments, incremental debt, liens, restricted payments and intellectual property transfers.
  • The company states the amendment does not increase its total indebtedness.

The filing

CompanyIntegra Lifesciences (IART)
Form8-K, current report
Filed with the SECJun 9, 2025, 6:30 AM ET
Accession number0000917520-25-000060

Items reported: 1.01 Material Definitive Agreement2.03 New Direct Financial Obligation

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 6:59 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on June 09, 2025.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.